

参考文献

- AmbroseAM, DeEDSF. (1947). The biological availability of l-ascorbyl palmitate. Arch Biochem. , 12(3):375-379.
- American Pharmaceutical Association. (1972). Guidelines for Biopharmaceutical Studies in Man. Washington D.C.: Academy of Pharmaceutical Sciences.
- BaileyGF, DuttonHJ, al.et. (1946). The content and biological availability of carotene in dehydrated carrots stored at high temperatures. Arch Biochem., 10:125-130.
- BaldwinRR, ThiessenJrR, McInroyEE. (1947). Physiological Availability of Iodine in Dithymol Diiodide. Science, 106(2753):317-319.
- BarrWH, GerbrachtLM, LetcherK, PlauMt, StrahlN. (1972). Assessment of the biologic availability of tetracycline products in man. Clin Pharmacol Ther, 13(1):97-108.
- BenetLZ. (1972). General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci., 61(4):536-541.
- BenetLZ. (2010). Clearance (née Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn, 37:529-539.
- BenetLZ. (2012). Benet L Z and Galeazzi R L: noncompartmental determination of the steady-state volume of distribution, J Pharm Sci 68, 1071-. The AAPS Journal, 14(2):164-167.
- BenetLZ, GaleazziRL. (1979). Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci, 68:1071-1074.
- BermanM, ShahnE, WeissMF. (1962). The routine fitting of kinetic data to models: A mathematical formalism for digital computers. Biophys J., 2:275-287.
- BermanM, WeissMF, ShahnE. (1962). Some formal approaches to the analysis of kinetic data in terms of linear compartmental systems. Biophys J. , 2:289-316.
- BialerM. (2007). Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia, 48(10):1825-1832.
- BochnerF, HooperWD, TyrerJH, EadieMJ. (1972). Factors involved in an outbreak of phenytoin intoxication. J Neurol Sci., 16(4):481-487.
- BoxenbaumH, BattleM. (1995). Effective half-life in clinical pharmacology. J Clin Pharmacol, 763-766.
- BriceGW, HammerHF. (1969). Therapeutic Nonequivalence of Oxytetracycline Capsules. JAMA, 208(7):1189-1190.
- BrodieBB, HellerWM (Ed). (1972). Bioavailability of Drugs. Basel: S. Karger.
- BuehlerG. (2010). History of Bioequivalence for Critical Dose Drugs. April 13, 2010 Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory

- Committee,
<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeForPharmaceuticalScienceandClinicalPharmacology/UCM209319.pdf>.
- BurtonME, ShawLM, SchentagJJ, EvansWE. (2006). Applied Pharmacokinetics & Pharmacodynamics Principles of therapeutic Drug Monitoring Fourth Edition. New York: Lippincott Williams & Wilkins.
- BurtT, JohnCS, RuckleJL, VuongLT. (2016). Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide. Expert Opin Drug Deliv, Sep 1:1-16.
- CasselmannWG, RappaportAM. (1954). Estimated hepatic blood flow and bromsulphalein clearance in dogs with experimental ischaemia of the liver. J Physiol, 183-187.
- CastleWB, AstwoodEB, FinlandM, KeeferCS. (1969). White Paper on the Therapeutic Equivalence of Chemically Equivalent Drugs Prepared by a Subcommittee of the Policy Advisory Committee, Drug Efficacy Study. JAMA, 208(7):1171-1172.
- CastleWB, AstwoodEB, FinlandM, KeeferCS. (1969). White Paper on the Therapeutic Equivalence of Chemically Equivalent Drugs. Prepared by a Subcommittee of the Policy Advisory Committee, Drug Efficacy Study. JAMA, 208(7):1171-1172.
- CDER, CBER. (2003). Exposure-Response Relationships – Study Design, Data Analysis, and Regulatory Applications. US FDA Guidance for Industry, <https://www.fda.gov/downloads/drugs/guidances/ucm072109.pdf>.
- CEDR. (2013). Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA (DRAFT). US FDA Guidance for Industry, <https://www.fda.gov/downloads/drugs/guidances/ucm377465.pdf>.
- ChapmanDG, ChattenLG, CampbellJA. (1957). Physiological availability of drugs in tablets. Can Med Assoc J., 76(2):102-106.
- ChapmanDG, CrisafioR, CampbellJA. (1954). The relation between in vitro disintegration time of sugar-coated tablets and physiological availability of riboflavin. J Am Pharm Assoc Am Pharm Assoc., 43(5):297-304.
- ChapmanDG, CrisafioR, CampbellJA. (1955). Reliability of the riboflavin excretion technique in determining availability of coated tablets. Can J Biochem Physiol., 33(5):753-7.
- ChenML, LeskoL, WilliamsRL. (2001). Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet, 40(8):565-572.

- ChesleyLC. (1944). Observations on the absorption, apparent volume of distribution, and excretion of thiourea. *J Clin Invest*, 856-858.
- ColburnWA. (1988). Combined pharmacokinetic/pharmacodynamic (PK/PD) modeling. *J Clin Pharmacol*, 28(9):769-771.
- CraigWA. (1998). Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men. *Clin Infect Dis*, 26(1):1-12.
- CraigWA, AndesD. (1996). Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. *Pediatr Infect Dis J*, 15(3):255-259.
- CraigWA, VogelmannB. (1987). The postantibiotic effect. *Ann Intern Med*, 106(6):900-902.
- CurranPF. (1960). Na, Cl, and water transport by rat ileum in vitro. *J Gen Physiol*, 43:1137-48.
- DartoisC, BrendelK, CometsE, LaffontMC, LaveilleC, TranchandB, . . . GirardP. (2007). Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. *Br J Clin Pharmacol*, 64(5): 603-612.
- Department of Health, Education, and Welfare, FDA. (1979). Therapeutically Equivalent Drugs Availability of List [21 CFR Part 20] [Docket No. 78N-0170]. *Federal Register*, January 12 (44 FR 2932).
- DollerE, DimockWW. (1946). Efficacy of various agents for delaying absorption of penicillin. *J Am Vet Med Assoc*, 108:310-313.
- DominguezR. (1934). Studies of renal excretion of creatinine II. Volume of distribution. *Proc. Soc. exp. Biol. Med.*, 1146-1150.
- DominguezR, PomereneE. (1945). Calculation of the rate of absorption of exogenous creatinine. *Proc. Soc. Exptl. Biol. Med.*, 173-181.
- DominguezR, CorcoranAC, PageIH. (1947). Mannitol: Kinetics of distribution, excretion, and utilization in human beings. *J. Lab. & Clin. Med.*, 1192-1202.
- DominguezR, GoldblattH, PomereneE. (1937). Kinetics of excretion and utilization of xylose. *Am J Physiol*, 429-438.
- DostFH. (1953). *Der Blütspiegel-Kinetik der Konzentrationsabläufe in der Kreislauf Flüssigkeit*. Leipzig: G. Thieme.
- DostFH. (1954). [Half value time and total clearance](German). *Z Gesamte Inn Med*, 546-551.
- EagleH. (1947). The inactivation of penicillins F, G, K and X by human rabbit serum. *J Exp Med*, 141-161.
- EagleH, FleischmanR, LevyM. (1953). Continuous vs. Discontinuous Therapy with Penicillin – The Effect of the Interval between Injections on Therapeutic Efficacy. *N Engl J Med*, 248:481-488.

- EagleH, FleishmanR, MusselmanA. (1950). Effect of schedule of sdministration on the therapeutic efficacy of pecicillin. Am J Med, 280-299.
- EagleHarry, MusselmanAD. (1948). The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med, 88(1):99-131.
- ElkintonJR. (1947). The volume of distribution of mannitol as a measure of the volume of extracellular fluid, with a study of the mannitol method. J Clin Invest, 1088-1097.
- EndrenyiL, FritschS, YanW. (1991). Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol, 29(10):394-399.
- FDA Advisory Committee Meeting: April 13, 2010 - Partial AUC. (2010). Minutes for the April 13, 2010 Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee. <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM210930.pdf>.
- FourieJZirkelbach, JacksonAJ, WangY, SchuirmannDJ. (2013). Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate. Pharm Res, 30(1):191-202.
- GarrettER, ThomasRC, WallachDP, AlwayCD. (1960). Psicofuranine: kinetics and mechanisms in vivo with the application of the analog computer. J Pharmac exp Ther, 130:106-118.
- GilbertDN. (1991). Once-daily aminoglycoside therapy. Antimicrob Agents Chemother, 35:399-405.
- GlazkoAJ, KinkelAW, AlegnaniWC, HplmesEL:. (1968). An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin Pharmacol Ther, 9(4):472-483.
- GoldnerAM, SchultzSG, CurranPF. (1969). Sodium and sugar fluxes across the mucosal border of rabbit ileum. J Gen Physiol. , 53(3):362-383.
- GrevilleGD. (1931). Study of the blood-calcium following the intravenous injection of calcium salts. Biochem. J., 1931-1942.
- HaggardHW. (1924). The absorption, distribution and elimination of ethyl ether I. The amount of ether absorbed in relation. J. Biol. Chem., 737-751.

- HaggardHW. (1924). The absorption, distribution and elimination of ethyl ether II. Analysis of the mechanism of absorption and elimination of such a gas or vapour as ethyl ether. *J. Biol. Chem.*, 753-770.
- HaggardHW. (1924). The absorption, distribution and elimination of ethyl ether V. Importance of the volume of breathing . *J. Biol. Chem.*, 795-802.
- HahnPF, WhippleGH. (1938). Iron methabolism in experimental anemia : "Availability of iron". *J Exp Med.*, 67(2):259-265.
- HamerJ, ChamberlainD. (1973). Biological availability of digoxin. *Br Med J*, 2(5859):177-178.
- HamiltomWF, MooreJW, KinsmanJM, SpurlingRG. (1931). Studies on the circulation IV. Further analysis of the injection method, and of changes in hemodynamics under physiological and pathological conditions. . *Am J Physiol*, 99:534-551.
- HarrisonLI, GibaldiM. (1977). Physiologically based pharmacokinetic model for digoxin distribution and elimination in the rat. *J Pharm Sci.*, 66(8):1138-1142.
- HauckWW, AndersonS. (1992). Types of bioequivalence and related statistical considerations. *Int J Clin Pharmacol Ther Toxicol*, 30(5):181-187.
- HauckWW, AndersonS. (1994). Measuring switchability and prescribability: when is average bioequivalence sufficient? *J Pharmacokinet Biopharm.* , 22(6):551-564.
- HaymanJ.M.Jr., HalstedA.J., SeylerE.L. (1933). A comparison of the creatinine and urea clearance tests of kidney function. *J Clin Invest*, 861-875.
- HearonJZ. (1961). A property of second order differential equations with application to formal kinetics. *Biophys J*, 1:581-587.
- HollisWA. (1872). Tissue Metabolism, or the Artificial Induction of Structural Changes in Living Organisms. *J Anat Physiol*, 6(Pt 2):381-512.
- JensenPE, KvoringSA, NorredamK. (1963). Probenecid as an adjuvant in the treatment of gonorrhoea with penicillin. *Br J Vener Dis*, 39:238-240.
- JohnsonBF, FowleAS, LaderS, FoxJ, Munro-FaureAD. (1973). Biological availability of digoxin from Lanoxin produced in the United Kingdom. *Br Med J*, 5(5):513-531.
- JokipiiSG, TurpeinenO. (1954). Kinetics of elimination of glucose from the blood during and after a continuous intravenous injection. *J. Clin. Invest.*, 452-458.
- JokipiiSG, TurpeinenO. (1954). Kinetics of elimination of glucose from the blood during and after a continuous intravenous. *J. Clin. Invest.*, 452-458.
- JolliffeN., SmithW.H. (1931). The excretion of urine in the dog 1. The urea and creatinine clearances. *Am. J. Physiol.*, 572-585.
- KarlssonMO, BealSL, SheinerLB. (1995). Three new residual error models for population PK/PD analyses. *J Pharmacokinet Biopharm*, 23(6):651-672.

- KruhøfferP. (1946). Inulin as an indicator for the extracellular space. *Acta Physiol. Scandinav.*, 16.
- KwanKC, BohidarNR, HwangSS. (1984). Estimation of an effective half-life. 著: BenetLZ, LevyG, FerraioloB, *Pharmacokinetics: a modern view.* (ページ: 147-162). New York: Plenum Press.
- LabovitzE, LevisonME, KayeD. (1974). Single-dose daily gentamicin therapy in urinary tract infection. *Antimicrob Agents Chemother*, 6(4):465-470.
- LeskoLJ, AtkinsonJr.AJ. (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. *Annu Rev Pharmacol Toxicol*, 41:347-366.
- LevyG., GibaldiG. (1974). Bioavailability of Drugs: Focus on Digoxin. *Circulation*, 49:391-394.
- LewisAE. (1948). The concept of hepatic clearance. *Am J Clin Pathol*, 789-795.
- LindenbaumJ, MellowMH, BlackstoneMO, ButlerVP. (1971). Variation in biologic availability of digoxin from four preparations. *N Engl J Med*, 285:1344-1347.
- LindenbaumJ. (1973). Bioavailability of digoxin tablets. *Pharmacol Rev*, 25(2):229-237.
- LozinskiE. (1960). Physiological Availability of Dicumarol. *Can Med Assoc J*, 83(4):177-178.
- MacLeodC, RabinH, RuedyJ, CaronM, ZarownyD, DaviesRO. (1972). Comparative bioavailability of three brands of ampicillin. *Can Med Assoc J.*, 107(3):203-209.
- MelnickD, HochbergM, OserBL. (1947). Physiological availability of the vitamins; influence of ascorbic acid stabilizers in fruits and vegetables. *J Nutr*, 34(4):409-420.
- MelnickD., HochbergM., OserB.L. (1945). Physiological availability of the vitamins. *J. Nutr.*, 30:67-79.
- MetzlerCM. (1969). NONLIN, a computer program for parameter estimation in nonlinear situations. Biostatistics Technical Report. 7292/69/7292/005. November 25. Kalamazoo.MI 49001, U.S.A: The Upjohn Company.
- MetzlerCM. (1969). NONLIN, a computer program for parameter estimation in nonlinear situations. Biostatistics Technical Report. Kalamazoo, USA: The Upjohn Company.
- MetzlerCM. (1974). Bioavailability--a problem in equivalence. *Biometrics*, 30(2):309-317.
- MetzlerCM, LevyG, MainlandD. (1969). A mathematical model for the pharmacokinetics of LSD effect. *Clin Pharmacol Ther.*, 10(5):737-740.
- MeyerMC, SlywkaGW, DannRE, WhyattPL. (1974). Bioavailability of 14 nitrofurantoin products. *J Pharm Sci*, 63(11):1693-1698.

- MöllerE, McIntoshJF, Van SlykeDD. (1928). STUDIES OF UREA EXCRETION. II: Relationship Between Urine Volume and the Rate of Urea Excretion by Normal Adults. *J Clin Invest*, 427-465.
- MoralesMF, ShockNW. (1944). A physical theory of acid anion displacement and recovery following exercise. *J. Gen. Physiol.*, 27:155-165.
- NagashimaR, LevyG, : O'ReillyRA. (1968). Comparative pharmacokinetics of coumarin anticoagulants. IV. Application of a three-compartmental model to the analysis of the dose-dependent kinetics of bishydroxycoumarin elimination. *J Pharm Sci.*, 57(11):1888-1895.
- NakaiK, FujitaM, OgataH. (2000). International harmonization of bioequivalence studies and issues shared in common. *Yakugaku Zasshi*, 120(11):1193-1200.
- OppenheimerJH, SchwartzNL, SurksMI. (1975). Determination of common parameters of iodothyronine metabolism and distribution in man by noncompartmental analysis. *J. Clin. Endocrin. of Metab.*, 41:319-324.
- OserBL, MelnickD, HochbergM. (1945). Physiological Availability of Vitamins. Study of Methods for Determining Availability of Vitamins in Pharmaceutical Products. *Ind. Eng. Chem. Anal. Ed.*, 17(7):405-411.
- PeckCC, RubinDB, SheinerLB. (2003). Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. *Clin Pharmacol Ther*, 73(6):481-490.
- PerlW. (1960). A method for curve-fitting by exponential functions. *Intern J Appl Radiat Isotopes*, 8:211-222.
- PortmannGA, McChesneyEW, StanderH, MooreWE. (1966). Pharmacokinetic model for nalidixic acid in man. I. Kinetic pathways for hydroxynalidixic acid. *J Pharm Sci.*, 55(1):59-62.
- PoulosPP. (1956). A constant-change (single injection) method for the estimation of the volume of distribution of substances in body fluid compartments. *J Clin Invest*, 921-933.
- RegameyC, KirbyWM. (1973). Pharmacokinetics of cephanone in healthy adult volunteers. *Antimicrob Agents Chemother*, 589-592.
- RenardL, SandersP, LaurentieM, DelmasJM. (1996). Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis. *J Vet Pharmacol Ther*, 19(2):95-103.
- RiegelmanS, LooJ, RowlandM. (1968). Concept of a volume of distribution and possible errors in evaluation of this parameter. *J. Pharm. Sci.*, 57:128-133.

- RiggsDS. (1963). The Mathematical Approach to Physiological Problems. Baltimore, MD.: Williams & Wilkins.
- RowlandM, BenetLZ, GrahamCG. (1973). Clearance concepts in pharmacokinetics. J. Pharmacok. Biopharm., 123-136.
- RowlandM, BenetLZ, GrahamCG. (1973). Clearance concepts in pharmacokinetics. J Pharmacok Biopharm, 123-136.
- SanchezN, SheinerLB, HalkinH, MelmonKL. (1973). Pharmacokinetics of digoxin: interpreting bioavailability. Br Med J, 4(5885):132-134.
- SapirsteinLA, VidtDG, MandelMJ, HanusekG. (1955). Volumes of distribution and clearance of intravenously injected creatinine in the dog. Am J Physiol, 181:330-336.
- SchallR, WilliamsRL. (1996). Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group. J Pharmacokinet Biopharm, 24(1):133-149.
- SchwartzIL, BreedES, MaxwellMH. (1950). Comparison of the volume of distribution, renal and rxtrarenal clearances of inulin and mannitol in man. J Clin Invest, 517-520.
- ShawTRD, HowardMR, HamerJ. (1972). Variation in the biological availability of digoxin. Lancet, 300:303-307.
- SheinerLB, SteimerJ-L. (2000). Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. Annu Rev Pharmacol Toxicol, 40(1):67-95.
- SteinijansVW, SauterR, JonkmanJH, SchulzHU, StrickerH, BlumeH. (1989). Bioequivalence studies: single vs multiple dose. Int J Clin Pharmacol Ther Toxicol., 27(5):261-266.
- SteinijansVW, SauterR, JonkmanJH, SchulzHU, StrickerH, BlumeH. (1989). Bioequivalence studies: single vs multiple dose. Erratum. Int J Clin Pharmacol Ther Toxicol, 27(7):366.
- StephensonJL. (1960). heory of transport in linear biological system - I. Fundamental integral equation. Bull Math Biophys, 22:1-17.
- StrongJM, DutcherJS, LeeWK, AtkinsonJr.AJ. (1975). Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther, 18(5 Pt 1):613-22.
- TaitJF, LittleB, TaitSA, FloodC. (1962). The metabolic clearance rate of aldosterone in pregnant and nonpregnant subjects estimated by both single-injection and constant-infusion methods. J. Clin. Invest., 41:2093-2100.

- TaitJF, TaitSAS, LittleB, LaumasKR. (1961). The disappearance of 7-H³-d-aldoosterone in the plasma of normal subjects. *J. Clin. Invest.*, 40:72-80.
- TaylorJD, WiegandRG. (1960). The analog computer and plasma drug kinetics. *Clin Pharmac Ther*, 3:464-472.
- TaylorT, ChasseaudLF, MajorRM, LeafFC, BonnR, DarraghA, LambeRF. (1985). Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. *Biopharm Drug Dispos.*, 6(2):119-129.
- Therapeutic non-equivalence. (1972). *Br Med J*, 3(5827):599-600.
- UnadkatJD, BarthaF, SheinerLB. (1986). Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. *Clin Pharmacol Ther*, 40(1):86-93.
- van Rossum, J. (1971). Significance of pharmacokinetics for drug design and the planning of dosage regimens. In E. Ariens, *Medicinal Chemistry Series Volume I* (p. 501). New York: Academic Press.
- Van SlykeDD, McIntoshJF, MöllerE, HannonRR, JohnstonC. (1930). STUDIES OF UREA EXCRETION: VI. Comparison of the Blood Urea Clearance with Certain Other Measures of Renal Function. *J Clin Invest*, 357-374.
- VittiTG, BanesD, ByersTE. (1971). Bioavailability of digoxin. *N Engl J Med.*, 285(25):1433-1434.
- WagnerJG. (1976). Linear pharmacokinetic equations allowing direct calculations of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. *J. Pharmacok. Biopharm.*, 4:443-467.
- WagnerJG. (1981). History of pharmacokinetics. *Pharmacol Ther*, 537-562.
- WagnerJG, NelsonE. (1963). Percent absorbed time plots derived from blood level and/or urinary excretion data. *J Pharm Sci*, 610-611.
- WagnerJG, NorthamMJI, AlwayCD, CarpenterOS. (1965). Blood levels of drug at the equilibrium state after multiple dosing. *Nature*, 207:1301-1302.
- WidmarkE., TandbergJ. (1924). Über die bedingungen für die Akkumulation Indifferenten Narkoliken. *Biochem. Z.*, 358-369.
- WidmarkEMP. (1919). Studies in the concentration of indifferent narcotics in blood and tissues. *Acta Med. Scandinav.*, 87-161.
- WidmarkEMP. (1932). Die theoretischen Grundlagen und die praktische Verwendbhzrkeit der gerichtlichmedizinischen Alkoholbestimmung. Berlin.
- YamaokaK, NakagawaT, UnoT. (1978). Statistical moments in pharmacokinetics. *J. Pharmacokinet. Biopharm.*, 6(6):547-558.

- 阿部正和. (1948). 血漿クリアランスの概念と其の臨床的應用. 医療, 64-67.
- 安原一, 渡部泰久, 笠原多嘉子, 坂本浩二. (1980). 寝たきり老人における Amikacin の血中動態. 臨床薬理, 207-213.
- 伊賀立二. (2000). 薬物動態試験の添付文書への反映. 薬物動態, 15(5):467-471.
- 伊藤隆太. (1975). 臨床薬理用語統一に当たって, 医学用語全般からみて注意すべき点と問題点. 臨床薬理, 277-282.
- 永井恒司. (1986). 新薬開発への薬剤学的アプローチ. 薬学雑誌, 99-109.
- 加藤隆一, 野口英世, 土屋為弘, 寺川雅人. (1974). 薬物の生体内動態からみたジクロフェナック (ボルタレン) の安全性について. 臨床薬理, 393-394.
- 花野学. (1971). Compartment theory. 臨床薬理, 135-146.
- 花野学. (1974). Bioavailability からみた製剤技術の進歩. 臨床薬理, 5(3):242-247.
- 花野学. (1975). Pharmacokinetics の用語の問題点. 臨床薬理, 6(4):291-298.
- 海老原昭夫, 田原一二, 芹沢淳. (1979). 血管拡張薬 CS-611 の健康人における薬物動態ならびに薬力学的検討. 臨床薬理, 89-90.
- 吉岡栄子, 仁志田博司, 久保博昭, 森口郁生, 勝呂信雄. (1980). 未熟児における Theophylline の Pharmacokinetics. 臨床薬理, 9-16.
- 高橋悟, 佐野隆志・染谷, 一彦, 篠崎公一, 増原慶壮, 田中美雄, 佐々木康人. (1985). 臨床薬物動態理論に基づく Amikacin 投与設計法の検討. 日本化学療法学会雑誌, 33(3):253-262.
- 今井康彦, 平岡聖樹, 安田早苗, 市原伴子, 貝原徳紀, 川合良成, . . . 中村光幹. (2005). 薬物動態-反応関係を活用した確実かつ効率的な用量選択に関する一考察. 臨床薬理, 36(5):247-253.
- 佐久間昭. (1982). 生物学的同等性試験における統計処理. 臨床薬理, 13(1):205-210.
- 笹征史, 内藤寛. (1987). 抗ウイルス薬 aciclovir の単回および多回服用時の薬物動態. 臨床薬理, 18(3):523-536.
- 笹征史, 内藤寛, ByeAlan, WhitemanPaul. (1983). 抗ウイルス薬 Acyclovir の薬物動態. 臨床薬理, 471-479.
- 山岡静三郎. (1972). 再び「臨床試験と臨床薬理に関する手引-FDA の一般指針」について. 臨床薬理, 173-175.
- 山下喬, 西山雅雄, 螺良英郎. (1976). OE-7 (ステアリン酸エリスロマイシンカプセル) に関する研究. The Japanese Journal of Antibiotics, 29(5):552-558.
- 篠崎公一, 平岡聖樹, 渋谷正則, 鈴木昭之 (監訳). (2009). 薬物動態学と薬力学の臨床応用 TDM の正しい理解のために. 東京: メディカル・サイエンス・インターナショナル.
- 秋元健. (1972). 臨床薬理学の範囲, 組織, 訓練について. WHO 研究グループによる報告 (WHO Technical Report Series No. 446, 1970). 臨床薬理, 59-69.

- 松丸秀夫, 他. (1974). 坐剤の吸収に関する研究-5-クロラムフェニコールの Bioavailability 変化におよぼす剤形の影響. 東京薬科大学研究年報, (通号 24):413-417.
- 新田邦宏, 三原潔, 緒方宏泰. (2003). インタビューフォームにおける薬物動態情報の現状と問題点. TDM 研究, 20(4):297-304.
- 石崎高志, 田原一二. (1974). 人と犬における β 受容体遮断剤, ソタロール (MJ-1999), の動態と効果の関係. 臨床薬理, 386-392.
- 石崎高志, 菅沼利之, 佐々木富男, 渡辺誠, 洞井由紀夫, 星宏, 足助渉. (1979). 筋注, 経口および直腸内における Ketoprofen Pharmacokinetics. 臨床薬理, 591-592.
- 石崎高志, 野村武夫, 安倍達. (1979). 抗炎症剤 Piroxicam の空腹時および食後における Pharmacokinetics. 臨床薬理, 589-590.
- 赤田節子, 下田通敏, 高橋靖侑, 斎藤嘉章. (1976). ガスクロマトグラフィーによる生体試料中のシンナリジンの定量法とそのバイオアベイラビリティ(製剤の生物学的利用率)について. 衛生化学, 22(5):291-295.
- 大橋京一, 橋本啓, 細田瑳一, 岡太一, 海老原昭夫, 小林捷治, 長倉明人. (1980). 新しい抗不整脈薬 Mexiletine の薬物動態と臨床効果. 臨床薬理, 365-366.
- 大森義仁. (1970). 前臨床薬理と臨床薬理との関連について. 臨床薬理, 38-40.
- 中野重行, 小川暢也, 河津雄介. (1979). Diazepam の Pharmacokinetics に及ぼす Neuroticism 水準の影響. 臨床薬理, 106-108.
- 中野重行, 小川暢也, 河津雄介, 福田廣. (1980). Alprazolam の健康人における薬物動態. 臨床薬理, 285-291.
- 田原一二, 石崎高志. (1978). β 遮断剤 Timolol の臨床薬理. 臨床薬理, 27-29.
- 田原一二, 佐藤待子, 中谷晴昭, 折内久美子, 佐藤光一, 石崎高志. (1976). イヌ, ヒト, ラットに於ける Sotalol 生体内動態と効果. 臨床薬理, 21-22.
- 田村善蔵. (1979). Phenytoin と Phenobarbital の血中濃度モニタリング. 臨床薬理, 657-658.
- 渡辺淳. (1974). バイオアベイラビリティの本(ブックガイド). ファルマシア, 10(6):415-416.
- 洞井由紀夫, 石崎高志, 渡辺誠, 可部順三郎. (1979). 喘息患者における Theophylline Loading Test に基づく至適投与設計の検討. 臨床薬理, 10(4):581-582.
- 買手哲美. (1963). 各種抗生剤の組織内および病巣内分布に関する研究. 日本化学療法学会雑誌, 257-265.
- 樋口駿 (監訳), 篠崎公一, 平岡聖樹, 川崎まさ江 (編集). (2013). 新訂 ウインターの臨床薬物動態の基礎 投与設計の考え方と臨床に役立つ実践法. 東京: 株式会社 じほう.
- 木村真太郎. (1977). 結晶セルロースと混合粉碎したフェニトインの溶解挙動とバイオアベイラビリティ. ファルマシア, 13(6):462.

- 柳浦才三, 宍戸愛子, 三戸秀敏, 西村友男, 小林登, 早川浩, 中川富士雄. (1979). 気管支喘息患児における Theophylline の血中動態の検討. 臨床薬理, 585-586.
- 鈴木徳治. (1984). 初回通過効果 : 生物学的利用性に影響する要因. ファルマシア, 20(1):21-24.